Pfizer will work with the Flagship-funded Quotient Therapeutics to conduct research that will inform drug development for cardiovascular and renal diseases.
Esperion’s ‘lipid lurkers’ take on cardiovascular disease
After Dr. Caitlin Hicks and her team revealed that some doctors appeared to be overusing lucrative vascular procedures, performing them on patients who may not have needed them, they received hostile pushback from across the profession.
Thousands of patients may be undergoing vascular procedures too soon or unnecessarily
A new analysis of Medicare claims by ProPublica and CareSet found that atherectomies, a procedure to treat vascular disease, were performed on about 30,000 patients who had questionable need for them.
Novo Nordisk’s semaglutide aces another cardio study, reduces heart failure
Novo’s findings, presented at the European Society of Cardiology Congress and published in the New England Journal of Medicine simultaneously, showed semaglutide resulted in greater weight loss in adults with heart failure with preserved ejection fraction and obesity.
Novo’s semaglutide reduces risk of heart issues by 20% in recent trial
The trial results point to the possibility of Novo’s semaglutide not only cutting weight for patients but also slashing the risk of heart disease and MACEs, too.
The American Heart Association is building a nation of lifesavers
A ProPublica investigation found that some doctors overuse invasive treatments for peripheral artery disease. So we talked to experts to learn what vascular patients should know when seeking care.
Cardiovascular disease is primed to kill more older adults, especially Blacks and Hispanics
Cardiovascular disease is poised to become more prevalent in the years ahead, disproportionately affecting Black and Hispanic communities and exacting an enormous toll on the health and quality of life of older Americans.